Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib
MK-7339-013
Phase 3 small_molecule active
Quick answer
Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib for Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease. is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active